GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Homology Medicines (Homology Medicines) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Apr. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison of Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



Homology Medicines  (NAS:FIXX) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Homology Medicines Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (Homology Medicines) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Executives
Paul Alloway officer: See Remarks C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour officer: Chief Scientific Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum officer: Chief Commercial Officer C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith officer: CFO, Treasurer & Secretary C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos director, officer: President & CEO C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly officer: See Remarks C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn director, 10 percent owner, other: *Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty officer: Chief Operating Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109

Homology Medicines (Homology Medicines) Headlines

From GuruFocus